Qingcong Lin

机构：Beijing Biocytogen (China)

发表论文 9 篇 · 总被引 18 次 · h-index 2

代表论文

• Abstract LB215: A first-in-class anti-TROP2/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor efficacy (2023 · Cancer Research · 被引 5)
• Abstract LB214: A first-in-class bispecific antibody-drug conjugate (DM002) targeting HER3 and the juxtamembrane domain of MUC1 (2023 · Cancer Research · 被引 4)
• Abstract LB212: BCG022: A novel bispecific antibody-drug conjugate targeting HER3 and MET (2023 · Cancer Research · 被引 2)
• Abstract LB216: Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer (2023 · Cancer Research · 被引 2)
• Abstract 2978: YH013, a novel EGFR x MET bispecific antibody-drug conjugate, exhibits potent antitumor efficacy (2023 · Cancer Research · 被引 2)
• Abstract LB213: Identification of DM004, a first-in-class anti-5T4/MET bispecific antibody-drug conjugate (2023 · Cancer Research · 被引 1)